- Molecular Epidemiology of Hepatitis B Virus
-
Kao JH
- KMID: 1022164
- Korean J Intern Med.
- 2011 Sep;26(3):255-261.
- doi: 10.3904/kjim.2011.26.3.255
Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
-
Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ
- KMID: 2515849
- Gut Liver.
- 2021 May;15(3):451-458.
- doi: 10.5009/gnl20218
Background/Aims: Fatty liver disease is defined as a cluster of diseases with heterogeneous etiologies, and its definition continues to evolve. The novel conceptional criteria for metabolic dysfunction-associated fatty liver disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
-
Wu JW, Kao JH, Tseng TC
- KMID: 2520835
- Clin Mol Hepatol.
- 2021 Oct;27(4):524-534.
- doi: 10.3350/cmh.2021.0012
Patients with chronic hepatitis B virus (HBV) infection are at risk of developing hepatocellular carcinoma (HCC), and serum markers reflecting viral replication are potential predictors for HCC development. Besides the... -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
-
Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH
- KMID: 2520841
- Clin Mol Hepatol.
- 2021 Oct;27(4):575-588.
- doi: 10.3350/cmh.2021.0155
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct comparison of biopsy techniques for hepatic malignancies
-
Huang SC, Liang JD, Hsu SJ, Hong TC, Yang HC, Kao JH
- KMID: 2514772
- Clin Mol Hepatol.
- 2021 Apr;27(2):305-312.
- doi: 10.3350/cmh.2020.0301
Background/Aims: The core needle biopsy (CNB), fine needle aspiration cytology (FNAC) and touch imprint cytology (TIC) are commonly used tools for the diagnosis of hepatic malignancies. However, little is known... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
-
Hsu YC, Tseng CH, Kao JH
- KMID: 2546375
- Clin Mol Hepatol.
- 2023 Oct;29(4):869-890.
- doi: 10.3350/cmh.2022.0420
Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk stratification of HBV infection in Asia-Pacific region
-
Kao JH
- KMID: 2069757
- Clin Mol Hepatol.
- 2014 Sep;20(3):223-227.
- doi: 10.3350/cmh.2014.20.3.223
Hepatitis B virus (HBV) infection is the major etiology of chronic liver disease worldwide and thus a global health problem, especially in Asia-Pacific region. The long-term outcomes of Asian HBV... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
-
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC
- KMID: 2540417
- Gut Liver.
- 2023 Mar;17(2):288-298.
- doi: 10.5009/gnl210551
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in... -
- CITED
-
- Close
- SHARE
-
- Close
- New perspectives of biomarkers for the management of chronic hepatitis B
-
Lin CL, Kao JH
- KMID: 2373145
- Clin Mol Hepatol.
- 2016 Dec;22(4):423-431.
- doi: 10.3350/cmh.2016.0069
With recent advances in molecular and genomic investigations, the impact of hepatitis B viral and host factors on the progression of chronic HBV infection has been explored. For viral factors,... -
- CITED
-
- Close
- SHARE
-
- Close
- Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
-
Lu MY, Huang CF, Hung CH, Tai C, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang S, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin C, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML, TACR Study Group
- KMID: 2549384
- Clin Mol Hepatol.
- 2024 Jan;30(1):64-79.
- doi: 10.3350/cmh.2023.0287
Background/Aims: Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to... -
- CITED
-
- Close
- SHARE
-
- Close
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
-
Cheng PN, Chen WJ, Hou CJY, Lin CL, Chang ML, Wang CC, Chang WT, Wang CY, Lin CY, Hung CL, Peng CY, Yu ML, Chao TH, Huang JF, Huang YH, Chen CY, Chiang CE, Lin HC, Li YH, Lin TH, Kao JH, Wang TD, Liu PY, Wu YW, Liu CJ
- KMID: 2549381
- Clin Mol Hepatol.
- 2024 Jan;30(1):16-36.
- doi: 10.3350/cmh.2023.0315
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels... -
- CITED
-
- Close
- SHARE
-
- Close
- Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
-
Tsai PC, Huang CF, Yeh ML, Hsieh MH, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai C, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Chen CY, Huang JF, Dai CY, Chung WL, Bair MJ, Yu ML, T-COACH Study Group
- KMID: 2557396
- Clin Mol Hepatol.
- 2024 Jul;30(3):468-486.
- doi: 10.3350/cmh.2024.0038
Background/Aims: Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for... -
- CITED
-
- Close
- SHARE
-
- Close
